Holen Sie sich die Stockscreener-App
3.70
8.81%
0.41
Schlusskurs vom Vortag:
$3.29
Offen:
$3.34
24-Stunden-Volumen:
224.87K
Relative Volume:
1.23
Marktkapitalisierung:
$152
Einnahmen:
-
Nettoeinkommen (Verlust:
$-31.97M
KGV:
-0.4479
EPS:
-8.2612
Netto-Cashflow:
$-5.66M
1W Leistung:
+16.23%
1M Leistung:
+3.77%
6M Leistung:
+6.55%
1J Leistung:
-43.58%
1-Tages-Spanne:
$3.33
$3.705
1-Wochen-Bereich:
$2.9101
$3.70
52-Wochen-Spanne:
$2.07
$14.85
Quantum Biopharma Ltd Stock (QNTM) Company Profile
Firmenname
Quantum Biopharma Ltd
Sektor
Branche
Telefon
-
Adresse
-
Compare QNTM vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QNTM
Quantum Biopharma Ltd
|
3.62 | 138 | 0 | -31.97M | -5.66M | -8.2612 |
VRTX
Vertex Pharmaceuticals Inc
|
521.74 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,004.21 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.49 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.88 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Quantum Biopharma Ltd Aktie (QNTM) Neueste Nachrichten
Quantum BioPharma receives FDA clearance for MS phase 2 trial - Investing.com
A multiple sclerosis drug candidate aimed at repairing nerve coating can now begin human testing - Stock Titan
Quantum Biopharma amends Form 6-K to add exhibit to F-3 registration statement - Bitget
Quantum Biopharma (QNTM) folds April 2 press release into shelf filing - Stock Titan
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach - Almaguin News
Why Did Quantum BioPharma (CN:TCM) Stock Surge 6.846% on 4 September 2026? - kalkine.ca
Quantum BioPharma engages FinnCom for investor awareness - scanx.trade
FDA Clears Quantum BioPharma’s Lucid-MS Phase 2 Trial — Could QNTM Be Entering a Pivotal Clinical Chapter? - kalkine.ca
Quantum BioPharma settles CAD$123,487 debt via Class B shares - scanx.trade
Quantum BioPharma Ltd. (NASDAQ: QNTM) Share Price, QNTM Stock News, QNTM Share Price & Updates - kalkine.ca
Quantum BioPharma Stock Slides 5.75%: Is Clinical Execution Risk Weighing on QNTM Sentiment? - kalkine.ca
Quantum BioPharma Stock Slides 5.75% as CN:QNTM Delisting Plans Add Fresh Pressure to QNTM Sentiment - kalkine.ca
Giving up one stock exchange but not Nasdaq, Quantum BioPharma (NASDAQ: QNTM) reshapes where its shares trade - Stock Titan
Quantum BioPharma to Delist Class B Shares from Canadian Securities Exchange - marketscreener.com
Quantum BioPharma Ltd. Applies for Voluntary Delisting of Class B Shares from Canadian Securities Exchange - Quiver Quantitative
Quantum BioPharma to Voluntarily Delist Class B Shares from CSE, Consolidating Trading on Nasdaq - kalkine.ca
Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange - Yahoo Finance
QNTM Initiated Coverage by Rodman & Renshaw -- Price Target Set at $8.00 - GuruFocus
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Draws ‘Buy’ Rating on Lucid-MS Potential - TradingView
Quantum BioPharma stock initiated with buy rating at Rodman & Renshaw - Investing.com Nigeria
Quantum BioPharma Ltd. (CN:QNTM) Rises 3.07% as FDA-Cleared Lucid-MS Program Strengthens Investor Optimism - kalkine.ca
QNTM Stock Analysis: Price-to-Sales Signals Market Skepticism De - GuruFocus
Quantum BioPharma Shares Slip 4.44% as Clinical Risk and Biotech Volatility Temper Sentiment - kalkine.ca
Headline: Quantum BioPharma Stock Under Pressure After August 25 Decline — Can Lucid-MS Catalyze a Recovery? - kalkine.ca
Quantum BioPharma Falls 4.26% After FDA Clearance Rally: Profit-Taking or a Deeper Signal? - kalkine.ca
Quantum Biopharma Provides Corporate Update - The Manila Times
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves - TradingView
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm - Benzinga
Quantum BioPharma Stock Gains 6.7% on FDA Clearance for Lucid-MS Phase 2 Trial - kalkine.ca
Quantum BioPharma Stock Under Pressure as Regulatory Uncertainty Tests the Lucid-MS Growth Story - kalkine.ca
Quantum BioPharma Stock Slides as Bearish Momentum, Funding Risk and Biotech Volatility Pressure CN:QNTM - kalkine.ca
Quantum (QNTM) Results Breakdown: The Latest Report Adds New Financial Reference Points under the Current Snapshot; Post-Earnings Trading: The Stock Records a 9.24% Decrease on the DayGuidance Revision Trend - vinanet.vn
Quantum BioPharma (QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2 - NewMediaWire
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2 - Benzinga
Quantum BioPharma Ltd (CN:QNTM) Gains Momentum as Clinical Breakthroughs Improve Investor Outlook - kalkine.ca
Quantum BioPharma Ltd Stock Intrinsic Values | HAM:0K91 - GuruFocus
Quantum BioPharma Ltd Stock Historical Valuations - GuruFocus
QNTM Q4 2025 Earnings: Loss of $0.71 Per Share Reported as Stock Advances 17.65%Revenue Report - Vinanet
Quantum BioPharma Ltd (HAM:0K91) Stock Earnings Transcripts - GuruFocus
Quantum BioPharma Ltd (HAM:0K91) Stock Price, Trades & News - GuruFocus
Who's Buying or Selling Quantum BioPharma Ltd (HAM:0K91) Stock Today? - GuruFocus
Quantum BioPharma (HAM:0K91) ROC (Joel Greenblatt) % : -34,873.53% (As of Mar. 2026) - GuruFocus
HAM:0K91 Dividend: Does Quantum BioPharma Ltd Pay a Dividend? - GuruFocus
Quantum BioPharma Ltd (HAM:0K91) Stock Price & 30 Year Financial Data - GuruFocus
Quantum BioPharma Ltd Stock Operating Data - GuruFocus
Quantum BioPharma Ltd (HAM:0K91) Competitors 2026 - GuruFocus
Quantum BioPharma Ltd (HAM:0K91)Valuation Measures & Financial Statistics - GuruFocus
Quantum BioPharma Ltd (HAM:0K91) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Quantum BioPharma Ltd (HAM:0K91) Valuation - GuruFocus
Quantum BioPharma Ltd (HAM:0K91) Stock News, Headlines & Updates - GuruFocus
Quantum BioPharma (HAM:0K91) EPS (Basic) : €-7.12 (TTM As of Mar. 2026) - GuruFocus
Finanzdaten der Quantum Biopharma Ltd-Aktie (QNTM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):